Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

Aurora Cannabis partners UK's Script Assist for easier patient access

EditorIsmeta Mujdragic
Published 02/28/2024, 07:24 AM
Updated 02/28/2024, 07:24 AM
© Reuters.

EDMONTON, AB - Aurora Cannabis Inc. (NASDAQ: NASDAQ:ACB) (TSX: ACB), a prominent player in the global medical cannabis market, has announced a new partnership with Script Assist, a UK-based medical cannabis prescription platform. This collaboration aims to enhance patient access to medical cannabis and provide comprehensive guidance throughout their treatment journey.

The Script Assist platform is designed to facilitate the prescription process for UK patients, offering a range of medical cannabis products from Aurora's portfolio. In March, the platform will expand its offerings to include three new flower products from Aurora's EU GMP-certified facilities in Canada. These products are Pedanios 26/1 EHD-CA (Electric Honey Dew), Pedanios 28/1 CMK-CA (Chemango Kush), and Pedanios 10/10 EQI-CA (Equiposa), featuring varying levels of THC and CBD.

Trisha Cassidy, Managing Director of Aurora UK & Ireland, emphasized the commitment to improving the UK medical cannabis landscape by providing patients with premium products and valuable information through Script Assist's innovative technology.

Script Assist will also launch a 'Find a Doctor' feature within its platform, simplifying the connection between patients and specialist prescribing doctors. This addition is expected to transform the medical cannabis prescription experience in the UK, with Aurora's full product range available through private doctors and clinics using the platform.

Aurora Cannabis, headquartered in Edmonton, Alberta, serves both medical and consumer markets with a diverse brand portfolio, including MedReleaf, CanniMed, Aurora, and Whistler Medical Marijuana Co. The company also holds a significant position in Bevo Farms Ltd., a top supplier of propagated agricultural plants in North America.

This news is based on a press release statement.

InvestingPro Insights

In light of Aurora Cannabis Inc.'s (NASDAQ: ACB) recent strategic partnership with Script Assist to improve patient access to medical cannabis in the UK, the company's financial health and stock performance are of particular interest to investors. According to InvestingPro, the company holds more cash than debt on its balance sheet, which may provide financial flexibility to support such initiatives. Additionally, two analysts have revised their earnings upwards for the upcoming period, hinting at a potentially brighter future for the company.

InvestingPro Data shows that Aurora Cannabis has a market capitalization of approximately $180.83 million USD. The company's Price to Earnings (P/E) ratio stands at 0.44, which is significantly lower than the adjusted P/E ratio for the last twelve months as of Q3 2024, which is 23.71. This discrepancy suggests that investors may be valuing the company's future earnings potential. Furthermore, with a Price to Book ratio of 0.47 as of Q3 2024, the company's stock is trading below the value of its assets, which could indicate an undervalued stock. However, the company's Revenue Growth for Q3 2024 was 5.45%, indicating a modest increase in sales.

For those interested in a deeper dive into Aurora Cannabis's financials and stock performance, there are additional InvestingPro Tips available at https://www.investing.com/pro/ACB, which offer comprehensive insights. Investors can also take advantage of a special offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, gaining access to all 11 additional InvestingPro Tips for Aurora Cannabis.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.